©2014 Advanstar Communications Inc. Wszystkie prawa zastrzeżone w języku polskim i angielskim. Artykuły tłumaczone z Contemporary OB/GYN za zgodą Advanstar Communications Inc. Jakiekolwiek kopiowanie w którymkolwiek języku, w części lub w całości, bez uprzedniego pisemnego zezwolenia Advanstar Communications Inc.i Medical Tribune Polska Sp. z o.o. całkowicie zabronione.

Piśmiennictwo

1. Lee, Y, Miron A, Drapkin R, et al. A candidate precursor to serous carcinoma that originates in the distal fallopian tube. J Pathol. 2007;211:26–35.

2. Crum CP, Drapkin R, Kindelberger D, Medeiros F, Miron A, Lee Y. Lessons from BRCa: The tubal fimbria emerges as an origin for pelvic serous cancer. Clin Med Res. 2007;5:35–44.

3. Leblanc E, Narducci F, Farre I, et al. Radical Fimbriectomy: a reasonable temporary risk-reducing surgery for selected women with a germ line mutation of BRCa 1 or 2 genes? Rationale and preliminary development. Gynecol Oncol. 2011:121:472–476.

4. Salvador S, Gilks B, Kobel M, Huntsman D, Rosen B, Miller D. The Fallopian Tube: Primary site of most pelvic high-grade serous carcinomas. Int J Gynecol Cancer. 2009;19:58–64.

5. Fathalla MF. Incessant ovulation—a factor in ovarian neoplasia? Lancet. 1971;2:163.

6. Cramer DW, Welch WR. Determinants of ovarian cancer risk. II. Inferences regarding pathogenesis. J Natl Cancer Inst. 1983;71(4):717–721.

7. Drapkin R, Karst AM. The new face of ovarian cancer modeling: Better prospects for detection and treatment. F1000 Med Reports. 2011;3:22.

8. Crum CP, Drapkin R, Miron A, et al. The distal fallopian tube: a new model of pelvic serous carcinogenesis. Curr Opin Obstet Gynecol. 2007;19:3–9.

9. Kindelberger DW, Lee Y, Miron A, et al. Intraepithelial carcinoma of the fimbria and pelvic serious carcinoma: Evidence for a causal relationship. Am J Surg Pathol. 2007;31:161–169.

10. Dietl J, Wischhusen J, Hausler SFM. The post-reproductive Fallopian tube: better removed? Hum Reprod. 2011;46(11):2918–2924.

11. Greene MH, Mai PL, Schwartz PE. Does bilateral salpingectomy with ovarian retention warrant consideration as a temporary bridge to risk-reducing bilateral oophorectomy in BRCa1/2 mutation carriers? Am J Obstet Gynecol. 2011;204:19.e1-6.

12. Green A, Purdie D, Bain C, et al. Tubal sterilization, hysterectomy and decreased risk of ovarian cancer. Survey of women’s Health Study group. Int J Cancer. 1997;71(6):948–951.

13 Hankinson SE, Hunter DJ, Colditz GA, et al. Tubal ligation, hysterectomy, and risk of ovarian cancer. a prospective study. JAMA.1993;270(23):2813–2818.

14. Berek JS, Chalas E, Edelson M, et al. Prophylactic and riskreducing bilateral salpingo-oophorectomy. Obstet Gynecol.2010;116(3):733–743.

15. Cass I, Walts a, Karlan BY. Does risk-reducing bilateral salpingo-oophorectomy leave behind residual tube? Gynecol Oncol. 2010;117:27–31

Do góry